Comparison of Gadovist and Magnevist in brain Magnetic resonance imaging of multiple sclerosis patients with an acute attack

IRCMJ logo
PDF
HTML

Keywords

Contrast media
Image enhancement
Magnetic resonance imaging
Multiple sclerosis

How to Cite

HashemiH., GhanaatiH., BehzadiS., HarirchianM. H., AmjadG., ShakibaM., GhavamiN., NaghibiH., & FirouzniaK. (2021). Comparison of Gadovist and Magnevist in brain Magnetic resonance imaging of multiple sclerosis patients with an acute attack. Iranian Red Crescent Medical Journal, 23(2). https://doi.org/10.32592/ircmj.2021.23.2.192

Abstract

Objective: The use of an appropriate contrast agent performs a major role in brain magnetic resonance imaging (MRI) of multiple sclerosis (MS) patients. The present study aimed to make a comparison between the diagnostic values of Gadovist and Magnevist considering the successive imaging times in contrast-enhanced brain MRI of MS patients.

Materials and Methods: A total of 62 relapsing-remitting MS patients (56 females, mean age of 31 years) were enrolled in the present study. All of them underwent two sessions of standard contrast-enhanced brain MRI upon enrollment and 48 h later. The participants were randomly assigned to each contrast agent. T1-weighted (T1W) images were taken 30 sec, as well as 5, 10, 15, and 30 min after the contrast injection. For all of the images, two neuro-radiologists who were blinded to the contrast type counted the number of plaques in the brain. In addition, for the enhanced plaques larger than 10 mm, the signal intensity (SI) was determined using its region of interest.

Results: The mean plaque number significantly increased from 30 sec to 15 min for both contrasts separately (P<0.001). Nonetheless, the slight increases in the mean plaque number from 15-30 min for both Gadovist and Magnevist were not statistically significant (both P-Values>0.25). The mean plaque number in the Gadovist group was higher, compared to that in the Magnevist group at both 15 and 30 min, and the differences were statistically on the borderline (both P-Values=0.07). The mean SI of enhanced plaques gradually increased in the course of imaging in both contrast groups. Except for 30 sec, in all other time sessions, the mean SI was higher in Gadovist-enhanced MR images, compared to Magnevist-enhanced MR images (P<0.01).

Conclusion: As evidenced by the obtained results, Gadovist showed a relatively better diagnostic value for brain MRI of MS patients. Furthermore, the findings suggested that it is cost-effective to take MRI only up to 15 min (instead of 30 min) after contrast injection in both agents.

https://doi.org/10.32592/ircmj.2021.23.2.192
PDF
HTML

References

  1. Hashemi H, Behzadi S, Ghanaati H, Harirchian MH, Yaghoobi M, Shakiba M, et al. Evaluation of plaque detection and optimum time of enhancement in acute attack multiple sclerosis after contrast injection. Acta Radiol. 2014;55(2):218-24. doi: 10.1177/0284185113495831. [PubMed: 23975149].
  2. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15(3):292-303. doi: 10.1016/S1474-4422(15)00393-2. [PubMed: 26822746].
  3. Young IR, Hall AS, Pallis CA, Bydder GM, Legg NJ, Steiner RE. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet. 1981;318(8255):1063-6. doi: 10.1016/s0140-6736(81)91273-3. [PubMed: 6118521].
  4. Bagheri MH, Meshksar A, Nabavizadeh SA, Borhani-Haghighi A, Ashjazadeh N, Nikseresht AR. Diagnostic value of contrast-enhanced fluid-attenuated inversion-recovery and delayed contrast-enhanced brain MRI in multiple sclerosis. Acad Radiol. 2008;15(1):15-23. doi: 10.1016/j.acra.2007.07.022. [PubMed: 18078903].
  5. Rovira A, León A. MR in the diagnosis and monitoring of multiple sclerosis: an overview. Eur J Radiol. 2008;67(3):409-14. doi: 10.1016/j.ejrad.2008.02.044. [PubMed: 18434066].
  6. Javid MA, Khan MA, Amin N, Nabi A. Calcification in Globus Pallidus and putamen of multiple sclerosis patients versus healthy subjects using quantitative susceptibility mapping. Iran J Radiol. 2016;13(4):e23636. doi: 10.5812/iranjradiol.23636. [PubMed: 27882200].
  7. Uysal E, Erturk SM, Yildirim H, Seleker F, Basak M. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5M and 1.0M gadolinium chelates for detecting multiple sclerosis lesions. AJR Am J Roentgenol. 2007;188(3):697-702. doi: 10.2214/AJR.05.2212. [PubMed: 17312056].
  8. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(11):2059-69. doi: 10.1093/brain/120.11.2059. [PubMed: 9397021].
  9. Janardhan V, Suri S, Bakshi R. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening. Radiology. 2007;244(3):823-31. doi: 10.1148/radiol.2443051171. [PubMed: 17690319].
  10. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840-6. doi: 10.1002/ana.20703. [PubMed: 16283615].
  11. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2. [PubMed: 29275977].
  12. Villar LM, García-Barragán N, Sádaba MC, Espiño M, Gómez-Rial J, Martínez-San Millán J, et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci. 2008;266(1-2):34-7. doi: 10.1016/j.jns.2007.08.030. [PubMed: 17884100].
  13. Maravilla KR . Enhancing our understanding of multiple sclerosis: tracking contrast-enhancing plaques with MR imaging. AJNR Am J Neuroradiol. 2001;22(4):601-3. [PubMed: 11290465].
  14. Davoudi Y, Foroughipour M, Torabi R, Layegh P, Matin N, Shoeibi A. Diffusion weighted imaging in acute attacks of multiple sclerosis. Iran J Radiol. 2016;13(2):e21740. doi: 10.5812/iranjradiol.21740. [PubMed: 27679697].
  15. Chan L, Sitoh Y, Chong J, See S, Umapathi TN, Lim S, Ong B. Application of the McDonald MRI criteria in multiple sclerosis. Ann Acad Med Singap. 2007;36(8):647-54. [PubMed: 17767335].
  16. Kharazi HH. New techniques in MRI give us the opportunity to have better detection, better evaluation of brain lesions. Iran J Radiol. 2017;5:e48324. doi: 10.5812/iranjradiol.48324.
  17. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007;6(8):677-86. doi: 10.1016/S1474-4422(07)70176-X. [PubMed: 17616439].
  18. Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2006;77(7):830-3. doi: 10.1136/jnnp.2005.073247. [PubMed: 16043456].
  19. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997;120(Pt 7):1149-61. doi: 10.1093/brain/120.7.1149. [PubMed: 9236628].
  20. Tintoré M, Rovira A, Martínez MJ, Rio J, Díaz-Villoslada P, Brieva L, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000;21(4):702-6. [PubMed: 10782781].
  21. Product monograph Gadovist. Global. Available at: URL: http://www.bayer.ca; 2017.
  22. Product monograph Magnevist. Global. Available at: URL: http://www.bayer.ca; 2017.
  23. Filippi M, Yousry T, Rocca MA, Fesl G, Voltz R, Comi G. Sensitivity of delayed gadolinium‐enhanced MRI in multiple sclerosis. Acta Neurol Scand. 1997;95(6):331-4. doi: 10.1111/j.1600-0404.1997.tb00220.x. [PubMed: 9228265].
  24. Esposito A, De Cobelli F, Sallemi C, Ravelli S, Del Maschio A. Cardiac magnetic resonance (CMR) for the diagnosis of acute myocarditis (AM): Comparison between single-dose 1M gadobutrol (Gadovist®) and double-dose 0.5 M gadolinium-DTPA (Magnevist®) in the detection of late enhancement (LE). Eur Cong Radiol. 2010;736:1-20. doi: 10.1594/ecr2010/C-0736.
  25. Anzalone N, Gerevini S, Scotti R, Vezzulli P, Picozzi P. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol. 2009;50(8):933-40. doi: 10.1080/02841850903095385. [PubMed: 19626475].
  26. Essig M, Anzalone N, Combs SE, Dörfler À, Lee SK, Picozzi P, et al. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol. 2012;33(5):803-17. doi: 10.3174/ajnr.A2640. [PubMed: 22016411].
  27. Giesel FL, Mehndiratta A, Risse F, Rius M, Zechmann CM, von Tengg-Kobligk H, et al. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla. Acta Radiol. 2009;50(5):521-30. doi: 10.1080/02841850902787685. [PubMed: 19337867].
  28. Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41(3):213-21. doi: 10.1097/01.rli.0000197668.44926.f7. [PubMed: 16481903].
  29. Yaghoobi M, Harirchian MH, Firouznia K, Behzadi S, Hashemi H, Ghanaati H, et al. The relationship between enhanced plaques with Gadovist and Magnevist contrast brain magnetic resonance imaging and the neurological deficit in the acute phase of relapsing remitting multiple sclerosis. Iran J Neurol. 2012;11(2):42-6. doi: 24250860.
  30. Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 C. Invest Radiol. 2008;43(12):817-28. doi: 10.1097/RLI.0b013e3181852171. [PubMed: 19002053].
  31. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, et al. Heterogeneity of blood‐brain barrier changes in multiple sclerosis: an MRI study with gadolinium‐DTPA enhancement. Neurology. 1990;40(2):229-35. doi: 10.1212/wnl.40.2.229. [PubMed: 2300240].
  32. Alizadeh A, Roudbari SA, Heidarzadeh A, Kouhsari M. Comparison between immediate and delayed imaging after gadolinium chelate injection for detecting enhanced lesions in multiple sclerosis. Iran J Radiol. 2010;7(4):235-9.